OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

Last updated: March 23, 2017
Sponsor: Optimer Pharmaceuticals LLC
Overall Status: Completed

Phase

2

Condition

Hyponatremia

Colic

Lactose Intolerance

Treatment

N/A

Clinical Study ID

NCT00097422
5119-022
OPT-80 Phase 2A
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with CDAD

Exclusion

Exclusion Criteria:

  • Patients with severe CDAD

Study Design

Study Start date:
November 01, 2004
Estimated Completion Date:
April 01, 2005

Study Description

This is a dose-finding study to select a safe and efficacious dose of OPT-80. Patients will be evaluated for safety and efficacy and pharmacokinetic parameters will be investigated.

Connect with a study center

  • Advanced Biologics

    New Hope, Pennsylvania 18938
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.